Eloxacinumab can be temporarily observed for transaminase elevation, if the transaminase level is significantly elevated, the drug should be promptly discontinued and liver-protecting medication should be given, and other possible causes of transaminase elevation should be investigated. Eloxizumab is a lipid-lowering drug, which usually does not cause transaminase elevation. Patients with mildly elevated aminotransferases can be temporarily observed without special treatment, and the changes in aminotransferases should be monitored dynamically. Patients with significantly elevated transaminases should actively search for causes of impaired liver function, such as whether they have viral hepatitis B, cirrhosis and other diseases. Adverse reactions to Eloxizumab Injection mainly include allergic reactions (rash, eczema, erythema, urticaria), upper respiratory tract infections, gastroenteritis, nasopharyngitis, dizziness, headache, back pain, muscle spasms, diarrhea, nausea, malaise, elevated blood pressure. This drug is contraindicated for those who are severely allergic to the drug. Patients usually need to strengthen the transaminase test, if there is an abnormality of transaminase, should promptly go to the hospital, under the guidance of the physician to give treatment.